Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

This study is for adults with relapsed (cancer returns) or refractory (cancer does not respond to treatment) Multiple Myeloma. Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell. The study aims to test a new drug called REGN5458 to see if it is safe and effective in treating this cancer.

Key points:

• This study involves different phases, with each phase testing the drug on patients with specific conditions.
• Participants will receive REGN5458 and be monitored for side effects and how well the drug works.
• Those who have had certain treatments before, like CAR-T cell therapy, may also be eligible.

The study will measure how well REGN5458 works in the body and its presence in the blood. Participants should have tried at least three other treatments before joining. People with certain other health issues or previous treatments are not eligible. Participation involves regular visits to the study site for tests and monitoring. If you decide to join, make sure you understand the commitment and any potential risks or benefits.